Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

9629	Companies
191458	Keywords
122917	Articles
102032	Press releases

Home
Companies
Theranexus

BRIEF

published on 01/08/2026 at 18:05, 3 days 5 hours ago

Publication of the letter to shareholders by Theranexus

Shareholders Neuroscience Rare Diseases Theranexus Drugs
BRIEF

published on 01/08/2026 at 18:05, 3 days 5 hours ago

THX Pharma Releases Shareholder Letter

Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
PRESS RELEASE

published on 01/08/2026 at 18:00, 3 days 5 hours ago

THX Pharma announces the publication of its letter to shareholders
THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included

Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF

published on 01/07/2026 at 08:05, 4 days 15 hours ago

THX Pharma appoints Julien Veys as Deputy General Manager

Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
BRIEF

published on 01/07/2026 at 08:05, 4 days 15 hours ago

THX Pharma Names Julien Veys as Deputy CEO

Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
PRESS RELEASE

published on 01/07/2026 at 08:00, 4 days 15 hours ago

THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer
THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases

Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
BRIEF

published on 11/13/2025 at 08:05, 1 month 28 days ago

THX Pharma successfully completes its €7.8 million capital increase

Investors Capital Increase New Actions Neurological Diseases THX Pharma
PRESS RELEASE

published on 11/13/2025 at 08:00, 1 month 28 days ago

THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure
THX Pharma successfully raises €7.8 million through capital increase, issuing 4,356,804 new shares at €1.80 each. Existing shareholders show strong support. Subscription period ran from Oct 29 to Nov 7, 2025, for the fully funded roadmap

Shareholders Capital Increase New Shares Subscription Period THX Pharma
BRIEF

published on 11/07/2025 at 18:05, 2 months 4 days ago

Theranexus: Publication of voting rights and shares as of October 31, 2025

Share Capital Voting Rights Biopharmaceutical Rare Diseases Theranexus
PRESS RELEASE

published on 10/23/2025 at 08:00, 2 months 19 days ago

THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million
THX Pharma launches a €8 million capital increase to fund rare neurological drug development, with 75.5% commitments secured. Batten-1 and TX01 to lead clinical and commercial endeavors with strategic shift to international markets. Investment opportunities for various tax schemes

Investment Capital Increase Drug Development Neurological Diseases THX Pharma

1 2 ... 6

Accesswire

Published on 01/10/2026 at 05:10, 1 day 18 hours ago

Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 22 hours ago

Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 2 days ago

Sun Peak Metals Grants Stock Options
Published on 01/09/2026 at 23:30, 2 days ago

Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 2 days ago

Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction

View all ACCESSWIRE

EQS Group

Published on 01/11/2026 at 22:20, 1 hour 13 minutes ago

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Published on 01/10/2026 at 21:25, 1 day 2 hours ago

CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 10 hours ago

SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 2 days 1 hour ago

Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 4 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 01/09/2026 at 18:30, 2 days 5 hours ago

H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 5 hours ago

January 2026
Published on 01/09/2026 at 17:45, 2 days 5 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 5 hours ago

Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 3 days 2 hours ago

Biannual report on SEB S.A.’S liquidity agreement

View all LES ECHOS COMFI WIRE